

[View this email in your browser](#)



RELIVE

International registry for patients with a relapsed or refractory hepatoblastoma or hepatocellular carcinoma

RELIVE *flash*

No.9 - February 2025

RELIVE: final evaluation of hepatoblastoma cohort in progress

As of today, 370 patients with various histologies have been documented in the RELIVE database. The following sites have contributed their patients:

US (Boston, Cincinnati, Spokane, UCSF, Salt Lake City, Houston)	66
Japan (22 institutions)	46
France (IGR Villejuif for French sites)	36
Hong Kong Children's Hospital	37
Prinses Maxima Centrum, Netherlands	33
Hospital for Sick Children, Toronto, Canada	32
Munich (pts from several institutions), Germany	35
Australia (Brisbane, Newcastle, Sydney, Adelaide, Perth)	24
Gdansk, Poland	11
Spain (Málaga, Sevilla, Barcelona, Valencia)	10
Belgium	8
Denmark	8
Switzerland (Geneva, Lausanne and Zurich)	6
Italy (Milano and Bari)	7

Today we present the short portrait of one of the key persons for the RELIVE project, Amy Opara, who plays a crucial role in completing the data of patients from the US. A big THANK YOU goes to her and all the others who have patiently worked with us over the past years!

The evaluation of the hepatoblastoma cohort is ongoing. It encompasses about 70% of the registered patients. Preliminary results have been discussed repeatedly during 2024. A small group of investigators has been charged by the Steering Committee to guide the evaluation and to write the manuscript on the hepatoblastoma cohort.

The team has issued several queries to clarify or complement data, please answer timely to help us define the cohorts with precision.

During the SIOPEL Spring Meeting of March 13-15 in Cardiff, results on hepatoblastoma patients will be presented and discussed in the plenary session.

RELIVE *people*

My name is **Amy Opara**, and I am a clinical research coordinator at the Dana-Farber Cancer Institute in Boston, Massachusetts. Over the past three years, I've had the privilege of working on several clinical trials investigating treatments for pediatric cancers, including relapsed/refractory hepatoblastoma and hepatocellular carcinoma. Under the guidance of our site principal investigator, Dr. Allison O'Neill, I've also had the great pleasure of contributing to the RELIVE study.



To date, our team has identified 10 eligible patients for the registry and have successfully abstracted their data into the REDCap database. Working on the RELIVE initiative has been an incredibly rewarding experience, as it has given me a deep appreciation for how global collaboration and extensive data sharing can refine diagnostic pathways and treatment protocols. I'm grateful to be involved in such a pivotal project, and I'm excited to see how the consortium's collective efforts help advance our understanding of pediatric hepatic tumors and improve outcomes for children worldwide.

